Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Neuraltus Pharmaceuticals

Request full access

Neuraltus Pharmaceuticals, Inc.

Palo Alto, United StatesFounded 2004Biotech & Life Sciences

About Neuraltus Pharmaceuticals

Neuraltus Pharmaceuticals, Inc. operated as a privately-held biopharmaceutical firm with a focus on creating treatments for neurodegenerative diseases. The company was founded in 2004 and established its headquarters in Palo Alto, California. Roland E. Dolle, Ph.D., served as a co-founder and held the position of Vice President of Chemistry.

The company's primary efforts were directed towards developing and commercializing therapeutics for conditions with significant unmet medical needs, particularly amyotrophic lateral sclerosis (ALS). Neuraltus' business model centered on advancing its drug candidates through the rigorous clinical trial process, a capital-intensive and lengthy endeavor typical of the biopharmaceutical industry. The ultimate goal was to gain regulatory approval and bring a new treatment to market for patients suffering from neurodegenerative disorders. The company engaged with global ALS specialists and patient advocacy groups to guide its clinical development strategy.

Its lead drug candidate was NP001, a small molecule regulator of macrophage activation. In individuals with ALS, inflammation in the central nervous system involves activated macrophages that can be toxic to neurons. NP001 was designed to convert these pro-inflammatory macrophages back to their normal, non-inflammatory state, thereby aiming to slow the progression of the disease and reduce neuronal damage. Despite promising initial studies, NP001 unfortunately failed to meet its primary and secondary endpoints in a Phase 2 clinical trial involving 138 ALS patients. Following the announcement of these trial results in early 2018, Neuraltus Pharmaceuticals ultimately ceased operations.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2004
Headquarters
Palo Alto, United States
Employees
4
Open positions
None listed
Dealroom signal
56.0/100
Industry
Health
Sub-industry
Pharmaceutical
Sector
Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Client focus
B2C

Funding history

6 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
EARLY VCOther financing May 2016 $15M $60M VantagePoint Capital Partners · Latterell Venture Partners —
EARLY VCOther financing Apr 2012 $1.5M $6M Adams Street Partners · Latterell Venture Partners —
Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Growth signals

Neuraltus Pharmaceuticals website traffic

Latest recorded traffic for Neuraltus Pharmaceuticals is 220 monthly website visits. Neuraltus Pharmaceuticals's team grew 0% over the past year.

Latest monthly visits220 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Neuraltus Pharmaceuticals in the Palo Alto ecosystem

Live from Dealroom

The Neuraltus Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

5 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A3 investors entered at this stage

Other known investors2 additional known investors

  • Stanford University
  • University of California, San Francisco
Team profiled 10 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Neuraltus Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Neuraltus Pharmaceuticals’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.